earnings
confidence high
sentiment positive
materiality 0.85
Halozyme reports record 2024 revenue of $1.015B, Q4 net income up 60% YoY
HALOZYME THERAPEUTICS, INC.
2024-FY EPS reported
$3.43
revenue$1,015,324,000
- Q4 total revenue $298M (+30% YoY); royalty revenue $170M (+40% YoY).
- Q4 GAAP EPS $1.06 (+63% YoY); non-GAAP EPS $1.26 (+54% YoY).
- Full-year 2024 total revenue $1,015M (+22% YoY); net income $444M (+58% YoY).
- Full-year adjusted EBITDA $632M (+48% YoY), exceeding guidance.
- Reiterates 2025 guidance: total revenue $1,150-1,225M, non-GAAP EPS $4.95-5.35.